John F Langenheim

6PUBLICATIONS
63CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 30, 2026
Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer.

|Aug 27, 2026
Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer.

|Oct 24, 2025
Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma.

Mandana Kamgar, G Aaron Hobbes, Raven Davidson

|Jan 18, 2023
High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer.

Inna Chervoneva, Amy R Peck, Yunguang Sun

|Nov 23, 2022
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP.

Thomas McFall, Michael Trogdon, Anita C Guizar

|Sep 15, 2021
NSG-Pro mouse model for uncovering resistance mechanisms and unique vulnerabilities in human luminal breast cancers.

Yunguang Sun, Ning Yang, Fransiscus E Utama

Pageof 1

Frequent Collaborators

4 joint publications

Thomas McFall

3 joint publications

Aniko Szabo

3 joint publications

Daniel Dorbin

3 joint publications

Juliannie Herrera